ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-OR117

Maternal Pregnancy Outcomes in Women with Complement-Mediated TMA: Update of the Vienna TMA Cohort

Session Information

Category: Women’s Health and Kidney Diseases

  • 2000 Women’s Health and Kidney Diseases


  • Gaggl, Martina M., Medical Universitiy of Vienna, Vienna, Austria
  • Haninger-Vacariu, Natalja, Medical Universitiy of Vienna, Vienna, Austria
  • Aigner, Christof, Medical Universitiy of Vienna, Vienna, Austria
  • Sunder-Plassmann, Gere, Medical Universitiy of Vienna, Vienna, Austria
  • Schmidt, Alice, Medical Universitiy of Vienna, Vienna, Austria

Pregnancy is a high-risk scenario to trigger complement pathway dysregulation. Presentation of paternal antigens activates the maternal alternative pathway and in women with malfunctioning complement regulatory proteins or C3 life-threatening thrombotic microangiopathy (TMA) can develop.


As of 2015 we reported outcomes of 27 pregnancies in 14 women with complement-mediated TMA (cTMA) enrolled in the Vienna TMA cohort (VTC). This work presents an update on this open cohort as of May 2019: Outcomes are CKD stage at last follow-up, incidence of dialysis or kidney transplantation (KTX) and death.


In 32 women of the VTC the mean age at first cTMA presentation was 30 ±16 years (figure 1). Up until 2019 in 25 women a total of 55 pregnancies were observed: 6 women 1, 9 women 2, 6 women 3, 2 women 4, 1 woman 5 pregnancies. In 14 women pregnancy occurred before diagnosis of cTMA (26 pregnancies, 6 abortions) with 8 pregnancies afterwards in 5 women. Pregnancy-associated cTMA (p-cTMA) happened in 11 women: 6 during first, 3 during second and 2 during a later pregnancy. Five women had 11 pregnancies following KTX.
Thirty-nine (71%) pregnancies were untreated and not complicated by p-cTMA. Four women received preventive plasma therapy for 6 pregnancies (2 KTX; 1 p-cTMA), 2 became pregnant during ongoing eculizumab therapy (3 pregnancies,1 KTX; 0 p-cTMA), 5 received therapeutic plasma therapy for p-cTMA (1 KTX), and 2 were switched to eculizumab (0 ESRD). At last follow-up 20 had eGFR ≥60ml/min per 1.73m2, 6 eGFR <60, 2 needed dialysis and 4 had died.


In summary, VTC data demonstrates good maternal outcome (1) in the majority of untreated pregnancies in women with a diagnosis of cTMA and (2) in specifically treated cTMA patients in a specialized center.

Figure 1.